Story

On air. The free wire runs 15 minutes behind live. See pricing

World, crypto, finance and tech news, scored for impact.

MarketsSEC EDGAR SCHEDULE 13GFiled 2 h ago

Vistagen Therapeutics, Inc.: BIOTECHNOLOGY VALUE FUND L P amends Schedule 13G stake filing

Open the sourceReported by SEC EDGAR SCHEDULE 13G, sec.gov, 16 November 2026, by SEC EDGAR SCHEDULE 13G

Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.

Biotechnology Value Fund L.P. amended its Schedule 13G stake filing for Vistagen Therapeutics, Inc., disclosing the change to the SEC under accession number 0000921895-26-003193. The filing signals a shift in the fund's passive position in the clinical-stage biopharmaceutical company. Investors watch 13G amendments for clues about institutional conviction in small-cap biotech names. Next, watch for further filings or 13D activity if the fund's stance becomes more active.

Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.

Named in this story

Vistagen Therapeutics, Inc., BIOTECHNOLOGY VALUE FUND L P